Global Vitamins Market Is Expected to Generate $59.2 Billion by 2031: Allied Market Research
February 16, 2023 09:05 ET
|
Allied Market Research
Portland, OR, Feb. 16, 2023 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global vitamins market garnered $28.8 billion in 2021, and is estimated to generate...
Cerulean Human Health Performance Welcomes Dr. Jamie Wright as Its New Medical Director
October 24, 2022 07:00 ET
|
CERULEAN Human Health Performance
SCOTTSDALE, Ariz., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Wright began his medical career in 2005 as a private practice Board-Certified Ob/Gyn. Recognizing his entrepreneurial predisposition, Dr. Wright...
IBN (InvestorBrandNetwork) Announces Latest Episode of The Bell2Bell Podcast featuring Amro Albanna, CEO of Aditxt, Inc.
August 02, 2022 08:17 ET
|
InvestorBrandNetwork (IBN)
LOS ANGELES, Aug. 02, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – IBN (InvestorBrandNetwork), a multifaceted communications organization engaged in connecting public companies to the investment...
The Ultimate Publishing House Launches the Bestseller Program
March 05, 2022 09:00 ET
|
Ultimate Publishing House
MIAMI, March 05, 2022 (GLOBE NEWSWIRE) -- The Ultimate Publishing House's seamless publishing formula makes becoming a published author easier than ever. In today's rapidly changing business...
AB Science announces the publication of the masitinib positive pivotal Phase 3 trial in progressive forms of multiple sclerosis in the journal Neurology® Neuroimmunology & Neuroinflammation
February 22, 2022 12:08 ET
|
AB Science
PRESS RELEASE PUBLICATION OF THE MASITINIB PIVOTAL PHASE 3 CLINICAL TRIAL IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS IN THE JOURNAL NEUROLOGY®: NEUROIMMUNOLOGY & NEUROINFLAMMATION Paris, 22...
AB Science annonce la publication de l’étude clinique pivot de Phase 3 du masitinib dans les formes progressives de la sclérose en plaques dans la revue Neurology® Neuroimmunology & Neuroinflammation
February 22, 2022 12:08 ET
|
AB Science
COMMUNIQUE DE PRESSE PUBLICATION DE L’ETUDE CLINIQUE PIVOT DE PHASE 3 DU MASITINIB DANS LES FORMES PROGRESSIVES DE LA SCLÉROSE EN PLAQUES DANS LA REVUE NEUROLOGY®: NEUROIMMUNOLOGY &...
Enterin and Their Collaborators at NIH Announce That Alpha-Synuclein, the Culprit in Parkinson's Disease, is Core and Central to Normal Immune Function
January 11, 2022 15:00 ET
|
Enterin Inc.
PHILADELPHIA, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and...
Sky Wellness Announces Collection of CBD Immunity Support Just in Time for Winter
December 17, 2021 14:50 ET
|
Sky Wellness
PHOENIX, Dec. 17, 2021 (GLOBE NEWSWIRE) -- As we get into the height of cold and flu season, Sky Wellness – a leading challenger brand in the CBD cpg industry – announces their collection of...
7 Hills Pharma Announces the Completion of a Landmark Phase I Trial of Immunostimulant to Improve Immuno-Oncology Drugs, COVID-19 and Influenza Vaccines
November 01, 2021 15:08 ET
|
7 Hills Pharma
HOUSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”), a clinical-stage drug development company bringing to market a platform of unique, first-in-concept oral small...
The Patch Brand Reimagines Health With Launch of Vitamin Patches
September 15, 2021 14:00 ET
|
The Patch Brand LLC
LOS ANGELES, Sept. 15, 2021 (GLOBE NEWSWIRE) -- The Patch Brand ushers in a wellness revolution with the launch of its easy-to-use vitamin patches containing the purest ingredients. The three...